Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06862791 · ClinicalTrials.gov registry record · Phase 2
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
A Phase 2 study of Obesity or Overweight, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 377
- Enrollment target
- 20
- Study locations
NCT06862791: Active Phase 2 study of Obesity or Overweight, sponsored by AstraZeneca.
NCT06862791 is a Phase 2 study of Obesity or Overweight that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 377 participants, below the 803-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06862791, a Phase 2 study of Obesity or Overweight, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 377 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.
Primary Outcome
To determine whether treatment with AZD9550 and AZD6234 in combination is superior to placebo for weight loss
Conditions Studied
Interventions
- DRUG AZD6234
- DRUG AZD9550
- DRUG Placebo comparator
Study Locations (20)
California
- Research Site - Cerritos
- Research Site - Escondido
- Research Site - Huntington Park
- Research Site - Lincoln
- Research Site - Sacramento
Alabama
- Research Site - Dothan
- Research Site - Vestavia Hills
Georgia
- Research Site - Decatur
- Research Site - Stockbridge
Indiana
- Research Site - South Bend
- Research Site - Valparaiso
Connecticut
- Research Site - Waterbury
Florida
- Research Site - Palm Harbor
Illinois
- Research Site - Champaign
Iowa
- Research Site - Sioux City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2026-05-25 |
| Phase | Phase 2 |
What the registry record for NCT06862791 still lists
NCT06862791 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, below the 803-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Obesity or Overweight appearing as the primary indexed condition, and to 3 interventions - of which AZD6234 is the first listed.
NCT06862791 names 20 study sites across 13 states, led by California, Alabama, Georgia.
Frequently Asked Questions
What is clinical trial NCT06862791 about?
NCT06862791 is a clinical study titled "A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone". The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at lea...
What is the current status of trial NCT06862791?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 377 participants. The study started on 2025-02-18. Estimated completion is 2026-05-25.
What conditions does trial NCT06862791 study?
This clinical trial studies the following conditions: Obesity or Overweight.
What interventions are being tested in trial NCT06862791?
The interventions under investigation include: AZD6234 (DRUG), AZD9550 (DRUG), Placebo comparator (DRUG).
Who is sponsoring clinical trial NCT06862791?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06862791 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity or Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes
RECRUITING · Phase 3
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI